#1081
|
||||
|
||||
Êîíòðîëü ÷àñòîòû ó áîëüíûõ ñ ïàðîêñèçìàëüíîé ôîðìîé ôèáðèëëÿöèèè ïðåäñåðäèé.
Âî âðåìÿ ïàðîêñèçìà ×ÑÑ, äîïóñòèì, 140/ìèíóòó. Ïàöèåíò ïðèíèìàåò, íàïðèìåð, áåòàëîê. ×ÑÑ ñíèæàåòñÿ äî ïðèåìëåìûõ öèôð. Ïàðîêñèçì ïðîõîäèò è íà ñèíóñîâîì ðèòìå íà ôîíå ìåòîïðîëîëà íåïðèåìëåìûå 40 óäàðîâ â ìèíóòó, à òî è íèæå. Êàê áûòü? Êàðäèîñòèìóëÿòîð? È äàëåå ëåãêî âåñòè íà êîíòðîëå ÷àñòîòû. À òàê ëè îí íóæåí, åñëè óæå ñîâñåì ñêîðî áóäåò ïîñòîÿííàÿ ôîðìà? Íàøè êàðäèîëîãè è òåðàïåâòû òàêèõ áîëüíûõ âåäóò î÷åíü ÷àñòî íà ïðîïàôåíîíå, õîòÿ ïðàêòè÷åñêè ó âñåõ ÈÁÑ. Âîçìîæíî ðèñê ïðåóâåëè÷åí, åñëè ïðàêòè÷åñêè íèêòî èç ïðàêòèêóþùèõ êàðäèîëîãîâ íå âèäèò óãðîçû îò ïðîïàôåíîíà ïðè ÈÁÑ? Åñëè ýôôåêòèâåí è íå ïðîòèâîïîêàçàí òàêæå íàçíà÷àþò êîðäàðîí. |
#1082
|
||||
|
||||
Öèòàòà:
1. Ïî÷èòàéòå ïðî ñèíäðîì òàõè-áðàäè â ó÷åáíèêàõ. 2. Ïîêàçàíèÿ ê ÂÝÊÑ è ÏÝÊÑ òîæå ëåãêî äîñòóïíû. 3. Ïðîïàôåíîí ÊÀÒÅÃÎÐÈ×ÅÑÊÈ ïðîòèâîïîêàçàí ïðè ÈÁÑ. Åãî íàçíà÷åíèå ïðè ÈÁÑ - ãðóáàÿ âðà÷åáíàÿ îøèáêè è èãíîðèðîâàíèå ìèðîâîãî îïûòà. "Âàøè êàðäèîëîãè" - óðîäû, äðóãîãî ñëîâà íå ïîäîáðàòü, ïðîñòèòå. ×èòàéòå èòîãè èññëåäîâàíèÿ CASH (îñòàíîâëåíî äîñðî÷íî!). Êòî íå âèäèò óãðîçû îò ïðîïàôåíîíà - òîãî íà ïåðåàòòåñòàöèþ!!! Êàê ìîæíî çà 2 äíÿ óâèäåòü îòäàëåííûé ïðîãíîç?! "Âàøè êàðäèîëîãè" - ïðîñòî óáèéöû.
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#1083
|
|||
|
|||
Ñåãîäíÿ âèäåë ïàöèåíòà ñ òðåïåòàíèåì ïðåäñåðäèé, ïðèíèìàâøåãî äëèòåëüíî äàáèãàòðàí 150 ìã 2 ðàçà â ñóòêè, ãîòîâèëñÿ íà Ð×À, ïî ×ÏÝÕÎÊà ñïîíòàííîå ýõî-êîíòðàñòèðîâàíèå â ËÏ, â óøêå ËÏ, ïî ÖÄÊ êðîâîòîêà â óøêå ËÏ íå îïðåäåëÿåòñÿ. Àðèòìîëîã ðåêîìåíäîâàë âìåñòî ïðàäàêñû âàðôàðèí. Àññîöèàòèâíî ñ ýòèì âîïðîñ - íå ïîÿâèëñÿ ëè êàêîé íîâûé êîíñåíñóñ èëè scientific statement ïî ïåðèïðîöåäóðàëüíîìó ïðèìåíåíèþ non-VKA-àíòèêîàãóëÿíòîâ ïðè Ð×À? âèäåë, ñòåñíÿþñü ñêàçàòü, â ôåéñáóêå ó êîëëåãè êàæåòñÿ ññûëêó íà ÷òî-òî ïîäîáíîå îò ESC - òåïåðü íàéòè íå ìîãó
|
#1084
|
||||
|
||||
Öèòàòà:
Several reports indicate that AF catheter ablation may be performed with fewer complications when oral warfarin anticoagulation is continued as an alternative to a bridging approach with UFH or LMWH (243,416–418). Several centers reported their experience with the use of direct thrombin and factor Xa inhibitors (mainly dabigatran) around the time of AF catheter ablation (244,324,419–422). Typically, dabigatran was held for 1 or 2 doses before the ablation procedure, in part reflecting the lack of a reversal agent. These reports suggest that the use of dabigatran is associated with a similar risk of bleeding and thromboembolic complications compared with uninterrupted warfarin; however, this is not a uniform finding (244) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] The 13th International Dead Sea Symposium (IDSS) on Innovations in Cardiac Arrhythmias and Device Therapy David InterContinental Hotel & Convention Center 12 Koifman Street, Tel Aviv ñîñòîèòñÿ 6 ìàðòà. Â ïðîãðàììå ïðèìåíåíèå àíòèêîàãóëÿíòîâ äî, âî âðåìÿ è ïîñëå êàòåòåðíîé àáëàöèè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#1085
|
|||
|
|||
Öèòàòà:
Guidelines for the Management of Patients With Atrial Fibrillation “In patients undergoing cardioversion or radiofrequency ablation for AF, use of warfarin or a DOAC is reasonable. Therapy should be given at least 3 weeks prior and 4 weeks following any cardioversion procedure. For patients undergoing radiofrequency ablation, continued use of warfarin, temporary interruption of dabigatran (24 hours pre- and post-procedure), and temporary interruption of rivaroxaban (held on day of procedure) are all safe”.[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#1086
|
||||
|
||||
Ê ñëîâó îá àíòèêîàãóëÿíòàõ.
Íåäàâíî ïðîø¸ë âýáèíàð ïî óñòàíîâêå îêêëþäåðîâ â óøêî ëåâîãî ïðåäñåðäèÿ. Îáùèå îùóùåíèÿ îò òåìû îêàçàëèñü íà óäèâëåíèå ïîçèòèâíûìè. Ïîõîæå ó äàííîé ìåòîäèêè âñå æå åñòü ïåðñïåêòèâû, ÈÌÕÎ äàæå áîëüøèå, ÷åì ó Ð×À. |
#1087
|
|||
|
|||
Çäðàâñòâóéòå, êîëëåãè! Ïðîøó ñîâåòà. Âîïðîñ: æåíùèíà 65 ëåò, ñòðàäàåò ÷àñòîé æåëóäî÷êîâîé ýêñòðàñèñòîëèåé 4á(ïîñëåäíèé õîëòåð 32 òûñ â ñóòêè), ÀÊØ â 2007 ã, ñåé÷àñ ÿâíîé ñòåíîêàðäèè íåò, èøåìèèè ïî Õì íåò. Àðèòìîëîãîì íàçíà÷åí ïðîïàíîðì 150 ìã 3 ðàçà, íà ôîíå ïðåïàðàòà -ÆÝÑ ïî÷òè íåò, Ð×À íå ðåêîìåíäîâàíà(íå çíàþ ïî÷åìó-âðà÷ ïðîñòî íàïèñàë ÷òî íå ïîêàçàíà). ß íàïðàâèëà åå ïîâòîðíî íà êîíñ ê àðèòìîëîãó, òàê êàê ìíå íå íðàâèòñÿ ïðîïàíîðì ïîñëå ÀÊØ. Áûë íàçíà÷åí áåòàëîê çîê-ïîñëå ÷åãî ÆÝÑ âíîâü ðåçêî óñèëèëàñü è áûë ñíÿò ïîñëåäíèé õîëòåð(32 òûñ, êóïëåòû, 1 êîðîòêàÿ ïðîáåæêà). îòìåíèëà áåòàëîê(íåýôôåêòèâåí)- íàçíà÷èëà êîðäàðîí- ïðèíèìàåò ïî 200 ìã 2 ðàçà 4 äíÿ-îòìå÷àåò óõóäøåíèå-÷àñòàÿ ýêñòðàñèñòîëèÿ, àóñêóëüòàòèâíî-êàæäûé 5-4 óäàð- ÆÝÑ. Áûâàåò îùóùåíèå òÿæåñòè çà ãðóäèíîé. Êàê áûòü?? ìîæåò áûòü ïðîïàíîðì â ñî÷åòàíèè ñ êîðäàðîíîì èëè Â-áëîêàòîðàìè íå áóäåò ñòîëü âðåäåí-èëè óäàñòüñÿ õîòÿ áû ñíèçèòü äîçó? Èëè íåò òàêèõ èññëåäîâàíèé? Ïîõîæå êîðäàðîí òîæå íå ýôôåêòèâåí. ×åì ïîìî÷ü?
|
#1088
|
||||
|
||||
Ýêñòðàñèñòîëû íå ïðèíÿòî ëå÷èòü àíòèàðèòìèêàìè. Ïðîïàíîðì ïðè ÈÁÑ îäíîçíà÷íî çëî. Êîñìåòè÷åñêèé ýôôåêò (óáðàòü ÝÑ ñ Õîëòåðà) íå ðàâåí ïðîãíîñòè÷åñêîìó (ò.å. ïðîäëèòü æèçíü; äîêàçàíî CAST è ïîñëåäóþùèìè èññëåäîâàíèÿìè).
×åëîâåê ïîñëå ÀÊØ äîëæåí ïîëó÷àòü: àíòèàãðåãàíòû, ñòàòèí, áåòàáëîêàòîð è èíãèáèòîð ÀÏÔ (èëè ñàðòàí). Ïîëó÷àåò? Êà÷åñòâåííîå ëå÷åíèå îñíîâíîãî çàáîëåâàíèÿ ñ ïðèöåëîì íà ïðîãíîç óëó÷øàåò è ñàìî÷óâñòâèå. Äîïîëíèòåëüíî ìîæíî îáðàòèòü âíèìàíèå íà ïîèñê àíåìèè èëè æåëåçîäåôèöèòà (ýòî óòÿæåëÿåò îñíîâíîå çàáîëåâàíèå è óõóäøàåò ïðîãíîç), à òàêæå âíåñåðäå÷íûå ïðîâîöèðóþùèå ôàêòîðû (ùèòîâèäíàÿ æåëåçà - ÒÒÃ, ãàñòðèò/ÿçâà - ÔÃÄÑ). ×òî íà ÝÊà ñ QTc?
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#1089
|
|||
|
|||
Öèòàòà:
|
#1090
|
||||
|
||||
Ìîæíî ïðèìåíèòü åùå ñî÷åòàíèå êîðäàðîíà (400 ìã) ñ áèñàïðîëîëîì (1,25 ìã, òèòðîâàòü ïî 1,25 ìã êàæäóþ íåäåëþ). Åñëè ýêñ çàâèñÿò îò ïîëîæåíèÿ òåëà, Â/ì õîíäðîïðîòåêòîðû.
|
#1091
|
|||
|
|||
ýòî âû ïðåäïîëàãàåòå ÷òî? ò. í. îñòåîõîíäðîç? ÿ íå â êóðñå - à õîíäðîïðîòåêòîðû ïðè ýòîì (ïðè îñòåîõîíäðîçå) èìåþò ñìûñë ñ ò. ç. äîêàçàòåëüíîé ìåäèöèíû? ß áû ïðè ñâÿçè ñ ïîëîæåíèåì òåëà ñêîðåå ïîäóìàë áû î ðåôëþêñå ãàñòðîýçîôàãàëüíîì èëè ãðûæå ÏÎÄ.
|
#1092
|
|||
|
|||
Êîëëåãè, ïðîñòèòå çà íàâåðíîå ñòðàííûé âîïðîñ. Æåùèíà 60 ëåò, ÀÄ â íîðìå, íå êóðèò, äèàáåòîì íå ñòðàäàåò, íàñëåäñòâåííîñòü íå îòÿãîùåíà, õîëåñòåðèí îêîëî 5 ììîëü/ë, ïî ôîðìóëàì îöåíêè ðèñêà - íèæå ïîðîãà ðåêîìåíäàöèè ñòàòèíîâ. Çà÷åì-òî ñäåëàíî óçè àðòåðèé íèæíèõ êîíå÷íîñòåé - ìåëêèå àòåðîìû â äèñòàëüíûõ îòäåëàõ ïðè ÊÈÌ 0.7 ìì. â ñîííûõ àðòåðèÿõ ÊÈÌ òàêæå â íîðìå, àòåðîì íåò. Íàçíà÷èëè áû âû åé ñòàòèíû? Ìíå êàæåòñÿ, ÷òî íå íàäî. Íî íå óâåðåí.
|
#1093
|
||||
|
||||
Öèòàòà:
Ñðåäè ìåäëåííîäåéñòâóþùèõ ïðåïàðàòîâ íàèáîëüøàÿ äîêàçàòåëüíàÿ áàçà ñîáðàíà â îòíîøåíèè õîíäðîèòèíà ñóëüôàòà (ÕÑ) è ãëþêîçàìèíà ñóëüôàòà (óðîâåíü äîêàçàòåëüíîñòè 1À). Ýòè ïðåïàðàòû áåçîïàñíû è õàðàêòåðèçóþòñÿ ìèíèìàëüíûì êîëè÷åñòâîì ïîáî÷íûõ ýôôåêòîâ. Ïî äàííûì ìåòààíàëèçà, âêëþ÷àâøåãî âñå îïóáëèêîâàííûå èññëåäîâàíèÿ ïî ýòîé ïðîáëåìå, âûðàæåííîñòü òåðàïåâòè÷åñêîãî ýôôåêòà äëÿ ÕÑ è ãëþêîçàìèíà ñóëüôàòà ñîñòàâèëà 0,78 è 0,44 ñîîòâåòñòâåííî. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îò ñåáÿ äîáàâëþ, ÷òî äëÿ êàðäèîëîãè÷åñêîãî áîëüíîãî àëüòåðíàòèâû õîíäðîïðîòåêòîðàì ïðîñòî íåò. |
#1094
|
||||
|
||||
Öèòàòà:
|
#1095
|
|||
|
|||
Öèòàòà:
ÍÀ ÂÝÌ åå íèêòî íå âîçüìåò -òàê êàê ýêñòðàñèñòîëû èäóò ïàðàìè. Íî íà ôîíå ïðîïàíîðìà-êîãäà ýêñòðàñèòîëèè íå áûëî äåëàëè ÕÌ ñ ëåñòíè÷íîé ïðîáîé- èøåìèè íå çàôèêñèðîâàíî, ïåðåíîñèò íàãðóçêè õîðîøî(íà ïðîïàíîðìå). Íà ÕÌ íå îòìå÷åíû ýïèçîäû óäëèíåíèÿ QT, íà ÝÊà QTc 0.4. Ïîñëåäíèé ÕÌ îò 3/03/16: Çà âðåìÿ ìîíèòîðèðîâàíèÿ ðåãèñòðèðîâàëñÿ ñèíóñîâûé ðèòì ñ ìàêñèìàëüíîé ×ÑÑ 120 óä/ìèí (14:48 ïî äíåâíèêó õîäüáà), ìèíèìàëüíîé ×ÑÑ 48 óä/ìèí(1:56ñîí), ñðåäíåé ×ÑÑ 64 óä/ìèí. Ýêòîïè÷åñêàÿ àêòèâíîñòü çíà÷èòåëüíî ïîâûøåíà: çà ñóòêè âûÿâëåíî 43838 ìîíîìîðôíûõ æåëóäî÷êîâûõ Ý/Ñ, â òîì ÷èñëå 557 êóïëåòîâ, 98 òðèïëåòîâ, 3068 ýïèçîäîâ áèãåìèíèè, 235 òðèãåìèíèè, à òàêæå 3 íàäæåëóäî÷êîâûõ Ý/Ñ, â òîì ÷èñëå 1 êóïëåò. Äèàãíîñòè÷åñêè çíà÷èìûõ îòêëîíåíèé ñåãìåíòà ST íå âûÿâëåíî. Çà ñóòêè 1 êëèíè÷åñêè çíà÷èìàÿ ïàóçà áîëåå 2 ñåê - ïîñòýêòîïè÷åñêàÿ â 2:27.(ýòî íà ôîíå áåòàëîê çîê 25 ìã-íàçíà÷àëà 50, íî áîëüíàÿ ïîáîÿëàñü èç-çà ðåäêîãî ïóëüñà ïðèíèìàòü ïîëíóþ äîçó). Áîþñü êîðäàðîí â äîçå 400+Â-áëîêàòîðû íàì íå ïîäîéäóò èç-çà áðàäèêàðäèè. Ìîæåò êîðäàðîí 100+áåòàëîê? Øóíòîãðàôèþ åé äåëàëè â íîÿáðå 2015-âñå ïðîõîäèìî ñî ñëîâ, áåç ñòåíîçîâ |